Woman and Man | 18 years and more
- | Country :
- France
- | organs :
- Tumeurs solides
- | Specialty :
- Thérapies Ciblées
Extract
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
Scientific Abstract
en cours d'intégration;